The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Phase II study update of navtemadlin in patients with myelofibrosis R/R to ruxolitinib
Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL, provides an update on a Phase II study investigating the MDM2 inhibitor, navtemadlin (KRT-232), as a treatment for patients with myelofibrosis (MF) who have relapsed after or are refractory to ruxolitinib. Dr Vachhani discusses the improvements observed in overall survival (OS) and progression-free survival (PFS) among patients treated with navtemadlin. These positive outcomes were associated with reductions in disease-modifying biomarkers including circulating CD34+ cell counts and driver gene variant allele frequency (VAF). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
